RT Journal Article
SR Electronic
T1 Inflammatory Bowel Disease and Neurodegenerative Disorders: Integrated Evidence from Mendelian Randomization, Shared Genetic Architecture and Transcriptomics
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.23.22275264
DO 10.1101/2022.05.23.22275264
A1 Ruijie Zeng
A1 Jinghua Wang
A1 Rui Jiang
A1 Jie Yang
A1 Chunwen Zheng
A1 Huihuan Wu
A1 Zewei Zhuo
A1 Qi Yang
A1 Jingwei Li
A1 Felix W Leung
A1 Weihong Sha
A1 Hao Chen
YR 2022
UL http://medrxiv.org/content/early/2022/05/25/2022.05.23.22275264.abstract
AB Objective Published observational studies have revealed the connection between inflammatory bowel disease (IBD) and neurodegenerative disorders, whereas the causality remains largely unclear. Our study aims to assess the causality and identify the shared genetic architecture between IBD and neurodegenerative disorders.Design A series of two-sample Mendelian randomization analyses were performed to assess the causality between IBD and neurodegenerative disorders (amyotrophic lateral sclerosis [ALS], Alzheimer’s disease [AD], Parkinson’s disease [PD], and multiple sclerosis [MS]). Shared genetic loci and functional interpretation were further investigated for IBD and ALS. The transcriptomic expressions of shared genes were evaluated in patients with IBD and ALS.Results Genetic predisposition to IBD is associated with lower odds of ALS (odds ratio [OR] 0.96, 95% confidence interval [CI] 0.94 to 0.99). In contrast, IBD is not genetically associated with an increased risk of AD, PD, or MS. Four shared genetic loci (rs6571361, rs10136727, rs7154847, and rs447853) were derived, and SCFD1, G2E3, HEATR5A were further identified as novel risk genes with enriched function related to membrane trafficking. G2E3 was differentially expressed and significantly correlated with SCFD1 in patients with IBD or ALS.Conclusion Our study reveals the casually protective role of IBD on ALS, and does not support the causality of IBD on AD, PD, or MS. Our findings indicate possible shared genetic architecture and pathways between IBD and ALS. The altered expressions of shared risk genes might contribute to the susceptibility to IBD and the protective effects for ALS. These results provide insights into the pathogenesis and therapeutics of IBD and neurodegenerative disorders.What is already known on this topicEmerging evidence has supported the communication between the gastrointestinal tract and central nervous system (the “gut-brain axis”).Published epidemiological studies have revealed the association between inflammatory bowel disease (IBD) and neurodegenerative disorders.The causality remains largely unclear.What this study addsGenetic liability to IBD is associated with a decreased risk of amyotrophic lateral sclerosis (ALS), whereas the susceptibility to IBD does not lead to Alzheimer’s disease, Parkinson’s disease, or multiple sclerosis.Shared genetic loci (rs6571361, rs10136727, rs7154847, and rs447853) and risk genes (SCFD1, G2E3, HEATR5A) are identified in IBD and ALS.Transcriptomic profiles in patients with IBD or ALS indicate that G2E3 is differentially expressed and significantly correlated with SCFD1.How this study might affect research, practice or policyThe findings provide insights into the pathogenesis and therapeutics of IBD and neurodegenerative disorders.Lower expression of G2E3 in IBD might serve as a protective factor to ALS.Unsubstantiated concerns among patients with IBD could be alleviated.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported by the National Natural Science Foundation of China (82171698, 82170561, 81300279, 81741067, 82100238), the Natural Science Foundation for Distinguished Young Scholars of Guangdong Province (2021B1515020003), the Guangdong Basic and Applied Basic Research Foundation (2022A1515012081), the Climbing Program of Introduced Talents and High-level Hospital Construction Project of Guangdong Provincial People's Hospital (DFJH201923, DFJH201803, KJ012019099, KJ012021143, KY012021183), and in part by VA Clinical Merit and ASGE clinical research funds (FWL).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGWAS summary statistics are available from the original manuscript of each study in Supplementary Table 1. Code used in this study is available from the corresponding authors upon reasonable request.